There’s a growing buzz around the Faculty’s Path to Patenting & Pre-commercialization (3P) grant program, now supporting its first innovative projects. It’s part of a long-term plan to finesse the most impactful health and biomedical research findings at uOttawa and kickstart opportunities for patenting and commercialization.
Dr. Daniel Figeys, Director of the uOttawa School of Pharmaceutical Sciences and Interim Director of Innovation and Partnerships, described it as a “very exciting” initiative to accelerate the development of spin-off and innovation at the Faculty of Medicine. He describes it as a paradigm-shifting vision at uOttawa that’s needed because the commercialization process, particularly for first-time inventors and entrepreneurs, can pose unique challenges.
“We didn’t want commercialization and innovation to just happen by chance. We wanted to facilitate the process and bring in experts. I think it’s the first step at the Faculty of Medicine to have a systematic process towards innovation and commercialization – and I think we will only see growth in that space over the next few years,” Dr. Figeys says.
Now, the uOttawa Faculty of Medicine is supporting three innovative research projects through the3P Program, which was launched in October 2021.